Table 2.
Clinical characteristics of our population.
| All patients (N = 94) | |
|---|---|
| Age at follow-up (years) | 60.30 ± 8.54 |
| Interscan period (years) | 6.11 ± 1.34 |
| Gender (male) | 57 (60.64%) |
| Current smoker | 13 (13.83%) |
| Family history of CAD | 49 (52.13%) |
| Co-morbidities | |
| Diabetes mellitus | 14 (14.89%) |
| Hypertension | 116 (58.29%) |
| Dyslipidemia | 68 (72.34%) |
| Obesity | 20 (21.28%) |
| Biochemical | |
| Triglycerides mg/dL | 113.81 ± 62.92 |
| Total cholesterol mg/dL | 185.55 ± 45.63 |
| LDL mg/dL | 108.16 ± 38.08 |
| HDL mg/dL | 55.96 ± 15.51 |
| Medications at discharge | |
| Aspirin | 51 (54.26%) |
| ARB | 13 (13.83%) |
| Beta-blocker | 37 (39.36%) |
| ACE inhibitors | 23 (24.47%) |
| Statin | 44 (46.81%) |
| Stenosis at baseline | |
| No stenosis | 17 (18.09%) |
| < 30% | 17 (36.17%) |
| 30–50% | 21 (22.34%) |
| 50–70% | 13 (13.83%) |
| 70–90% | 6 (6.38%) |
| > 90% | 3 (3.19%) |
LDL low density lipoprotein, HDL high density lipoprotein, ARB Angiotensin II Receptor Blockers, ACE Angiotensin-converting enzyme.